Skip to main content
Clinical Trials/NCT05938738
NCT05938738
Recruiting
Not Applicable

A Portable Dyspnea Relief Device for Episodic Breathlessness in COPD (PEP-buddy): Effect on Dyspnea Severity and Mechanism of Action

University Medical Center Groningen2 sites in 1 country25 target enrollmentJanuary 31, 2024
ConditionsCOPD
InterventionsPEP-buddy

Overview

Phase
Not Applicable
Intervention
PEP-buddy
Conditions
COPD
Sponsor
University Medical Center Groningen
Enrollment
25
Locations
2
Primary Endpoint
Dyspnea severity
Status
Recruiting
Last Updated
8 days ago

Overview

Brief Summary

Chronic dyspnea is the most characteristic symptom of patients with Chronic Obstructive Pulmonary Disease (COPD), with intermittent increases during exercise and other events.Despite optimal standard therapy, episodic dyspnea is a common occurrence in COPD. Recently, the PEP buddy was developed which is an easy-to use, hands-free device that generates positive expiratory pressure (PEP). Although currently the available evidence is limited, it indicates that utilizing the PEP-buddy can result in enhancements in dyspnea during exertion, exertional desaturation and overall quality of life. More research is needed to evaluate the effectiveness of this device and the long term usability, as well as getting more insight in the mechanism of action. Therefore, the aim of our study is to explore the potential of this device for patients with COPD and episodic breathlessness.

Registry
clinicaltrials.gov
Start Date
January 31, 2024
End Date
December 31, 2026
Last Updated
8 days ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

JE Hartman

Principal investigator

University Medical Center Groningen

Eligibility Criteria

Inclusion Criteria

  • Age ≥40 years
  • Read, understood and signed Informed Consent
  • COPD Gold class II-IV/ B or E (FEV1\<60% of predicted, CAT ≥10 points)
  • 5\. Optimized standard therapy according to the study physician
  • Episodic breathlessness requiring intervention (i.e. taking rest during physical activities, as needed inhalation medication, breathing techniques, as needed opioids) at least three days per week

Exclusion Criteria

  • Other severe disease causing episodic breathlessness
  • Life expectancy ≤ 3 months
  • Exacerbation of COPD 4 weeks prior to inclusion
  • Change in COPD management targeted at breathlessness 8 weeks prior to inclusion
  • Inability to use the PEP buddy device
  • Currently participating in another interventional clinical study
  • Any other conditions, which, in the opinion of the investigator would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study.

Arms & Interventions

PEP-buddy

Patients will use the PEP-buddy as needed.

Intervention: PEP-buddy

Outcomes

Primary Outcomes

Dyspnea severity

Time Frame: 4 weeks

To investigate the effect of the portable dyspnea relief device on dyspnea severity after 4 weeks. Dyspnea severity is measured by the dyspnea domain of the chronic respiratory questionnaire (CRQ), this score of this scale ranges from 5-35, with a higher score indicating more severe dyspnea.

Study Sites (2)

Loading locations...

Similar Trials